Erratum: Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration (Advances in Therapy (2013) 30 (1111-1127) DOI: 10.1007/s12325-013-0078-4);Retrospective analysis of first-line anti-vascular endothelial growth factor treatment patterns in wet age-related macular degeneration

Advances in Therapy

Volumn 30, Issue 12, 2013, Pages 1111-1127

  Johnston, Stephen S ^a   Wilson, Kathleen ^a   Huang, Alice ^a   Smith, David ^a   Varker, Helen ^a   Turpcu, Adam ^b  

^a IBM WATSON HEALTH   (United States)

^b GENENTECH INC   (United States)

Author keywords

Anti vascular endothelial growth factor; Healthcare expenditures; Healthcare utilization; Intravitreal; Ophthalmology; Retrospective wet age related macular degeneration

Indexed keywords

AFLIBERCEPT; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; STANDARD; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT; AGE; ANTAGONISTS AND INHIBITORS; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; ECONOMICS; EVALUATION STUDY; FACTUAL DATABASE; INTRAVITREAL DRUG ADMINISTRATION; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICAL MODEL; TIME; UNITED STATES; WET MACULAR DEGENERATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; COST-BENEFIT ANALYSIS; DATABASES, FACTUAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; INTRAVITREAL INJECTIONS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POISSON DISTRIBUTION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84890570048     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0087-3     Document Type: Erratum

References (11)

1. Leibowitz HM, Krueger DE, Maunder LR, et al. The Framingham Eye Study Monograph. VI. Macular degeneration. Surv Ophthalmol. 1980;24(suppl):428-57.
2. Klein R, Chou CF, Klein BE, Zhang X, Meuer SM, Saaddine JB. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol. 2011;129(1):75-80.
3. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Study. Ophthalmology. 1992;99:933-43.
4. American Academy of Ophthalmology. age-related macular degeneration preferred practice pattern - updated October 2011. http://one.aao.org/preferred- practice-pattern/agerelated-macular-degeneration-ppp-september-200. Accessed 14 Sept 2013.
5. Ferris FL III, Fine SL, Hyman LA. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-2.
6. Macugen [package insert]. San Dimas, CA: Gilead Sciences, Inc; 2011.
7. Lucentis [package insert]. South San Francisco, CA: Genentech, Inc.; 2013.
8. Eylea [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2013.
9. Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-56.
10. National Center for Health Statistics. The International Classification of Diseases, Ninth Revision, Clinical Modification. http://www.cdc.gov/nchs/icd/ icd9cm.htm.
11. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-9.